Kilitch Historical Income Statement

KILITCH Stock

315.60 4.95 1.59%

Historical analysis of Kilitch Drugs income statement accounts such as Total Revenue of 889.7 M can show how well Kilitch Drugs Limited performed in making a profits. Evaluating Kilitch Drugs income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Kilitch Drugs's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Kilitch Drugs Limited latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kilitch Drugs Limited is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kilitch Drugs Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About Kilitch Income Statement Analysis

Kilitch Drugs Limited Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Kilitch Drugs shareholders. The income statement also shows Kilitch investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Kilitch Drugs Income Statement Chart

As of now, Kilitch Drugs' EBITDA is decreasing as compared to previous years. The Kilitch Drugs' current Cost Of Revenue is estimated to increase to about 969.4 M, while Depreciation And Amortization is projected to decrease to under 32.6 M.

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses

Total Revenue

Total revenue comprises all receipts Kilitch Drugs Limited generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Kilitch Drugs Limited minus its cost of goods sold. It is profit before Kilitch Drugs operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Kilitch Drugs Limited. It is also known as Kilitch Drugs overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Kilitch Drugs' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Kilitch Drugs Limited current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kilitch Drugs Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2021	2022	2023	2024 (projected)
Gross Profit	488.0M	648.4M	620.5M	310.3M
Total Revenue	1.1B	1.4B	1.5B	889.7M

Gross Profit Total Revenue

Kilitch Drugs income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling And Marketing Expenses	Net Income From Continuing Ops	Minority Interest	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation
Depreciation And Amortization		-0.03	-0.25	-0.14	-0.1	-0.06	-0.07	-0.06	0.04	-0.15	0.19	-0.07	0.12	-0.1	0.03	0.47	-0.65	-0.29	-0.21	0.08	-0.14	-0.03
Interest Expense	-0.03		0.04	0.79	0.74	0.8	0.41	0.45	0.45	0.9	0.65	0.38	0.05	0.38	0.37	0.12	0.74	0.27	0.77	-0.96	0.89	0.86
Selling General Administrative	-0.25	0.04		-0.09	-0.03	-0.12	-0.14	-0.16	-0.19	-0.1	-0.09	-0.15	-0.18	-0.13	-0.19	0.16	0.13	-0.06	0.02	-0.09	0.06	0.08
Total Revenue	-0.14	0.79	-0.09		0.97	0.99	0.52	0.56	0.55	0.92	0.84	0.51	0.19	0.5	0.57	0.03	0.71	0.4	0.77	-0.75	0.71	0.79
Gross Profit	-0.1	0.74	-0.03	0.97		0.96	0.38	0.41	0.4	0.82	0.92	0.36	0.05	0.36	0.44	0.15	0.65	0.48	0.76	-0.73	0.7	0.81
Other Operating Expenses	-0.06	0.8	-0.12	0.99	0.96		0.52	0.56	0.55	0.91	0.88	0.5	0.21	0.5	0.58	0.07	0.65	0.4	0.74	-0.74	0.71	0.8
Operating Income	-0.07	0.41	-0.14	0.52	0.38	0.52		1.0	0.99	0.57	0.24	1.0	0.9	1.0	0.97	-0.4	0.32	-0.08	0.1	-0.15	0.1	0.14
Ebit	-0.06	0.45	-0.16	0.56	0.41	0.56	1.0		0.99	0.61	0.28	1.0	0.88	0.99	0.97	-0.36	0.35	-0.03	0.15	-0.2	0.16	0.18
Ebitda	0.04	0.45	-0.19	0.55	0.4	0.55	0.99	0.99		0.6	0.3	0.99	0.9	0.99	0.98	-0.31	0.28	-0.06	0.13	-0.19	0.15	0.18
Cost Of Revenue	-0.15	0.9	-0.1	0.92	0.82	0.91	0.57	0.61	0.6		0.67	0.55	0.21	0.55	0.57	-0.02	0.79	0.34	0.82	-0.82	0.79	0.74
Total Operating Expenses	0.19	0.65	-0.09	0.84	0.92	0.88	0.24	0.28	0.3	0.67		0.22	0.01	0.22	0.33	0.35	0.37	0.47	0.61	-0.65	0.62	0.76
Income Before Tax	-0.07	0.38	-0.15	0.51	0.36	0.5	1.0	1.0	0.99	0.55	0.22		0.91	1.0	0.98	-0.39	0.3	-0.06	0.09	-0.12	0.09	0.11
Total Other Income Expense Net	0.12	0.05	-0.18	0.19	0.05	0.21	0.9	0.88	0.9	0.21	0.01	0.91		0.91	0.89	-0.38	-0.1	-0.24	-0.29	0.22	-0.25	-0.2
Net Income	-0.1	0.38	-0.13	0.5	0.36	0.5	1.0	0.99	0.99	0.55	0.22	1.0	0.91		0.97	-0.42	0.32	-0.07	0.08	-0.13	0.09	0.12
Income Tax Expense	0.03	0.37	-0.19	0.57	0.44	0.58	0.97	0.97	0.98	0.57	0.33	0.98	0.89	0.97		-0.28	0.24	-0.01	0.14	-0.12	0.11	0.14
Selling And Marketing Expenses	0.47	0.12	0.16	0.03	0.15	0.07	-0.4	-0.36	-0.31	-0.02	0.35	-0.39	-0.38	-0.42	-0.28		-0.21	0.27	0.28	-0.22	0.34	0.13
Net Income From Continuing Ops	-0.65	0.74	0.13	0.71	0.65	0.65	0.32	0.35	0.28	0.79	0.37	0.3	-0.1	0.32	0.24	-0.21		0.36	0.79	-0.76	0.73	0.65
Minority Interest	-0.29	0.27	-0.06	0.4	0.48	0.4	-0.08	-0.03	-0.06	0.34	0.47	-0.06	-0.24	-0.07	-0.01	0.27	0.36		0.51	-0.35	0.54	0.26
Tax Provision	-0.21	0.77	0.02	0.77	0.76	0.74	0.1	0.15	0.13	0.82	0.61	0.09	-0.29	0.08	0.14	0.28	0.79	0.51		-0.84	0.87	0.72
Net Interest Income	0.08	-0.96	-0.09	-0.75	-0.73	-0.74	-0.15	-0.2	-0.19	-0.82	-0.65	-0.12	0.22	-0.13	-0.12	-0.22	-0.76	-0.35	-0.84		-0.94	-0.92
Interest Income	-0.14	0.89	0.06	0.71	0.7	0.71	0.1	0.16	0.15	0.79	0.62	0.09	-0.25	0.09	0.11	0.34	0.73	0.54	0.87	-0.94		0.82
Reconciled Depreciation	-0.03	0.86	0.08	0.79	0.81	0.8	0.14	0.18	0.18	0.74	0.76	0.11	-0.2	0.12	0.14	0.13	0.65	0.26	0.72	-0.92	0.82

Click cells to compare fundamentals

Kilitch Drugs Account Relationship Matchups

Kilitch Drugs income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	20.0M	19.9M	24.7M	35.5M	33.5M	32.6M
Interest Expense	7.2M	7.5M	12.0M	49.2M	60.4M	63.4M
Selling General Administrative	15.2M	20.1M	12.3M	19.9M	37.6M	25.0M
Total Revenue	533.2M	685.2M	1.1B	1.4B	1.5B	889.7M
Gross Profit	242.3M	312.2M	488.0M	648.4M	620.5M	310.3M
Other Operating Expenses	548.1M	647.7M	1.1B	1.3B	1.3B	831.4M
Operating Income	(8.4M)	41.3M	100.2M	148.6M	208.1M	218.5M
Ebit	25.5M	60.0M	109.5M	171.0M	252.8M	265.5M
Ebitda	45.5M	79.8M	134.1M	206.5M	286.3M	300.7M
Cost Of Revenue	290.9M	373.1M	654.3M	747.6M	923.2M	969.4M
Total Operating Expenses	257.2M	274.6M	398.7M	508.2M	412.4M	252.4M
Income Before Tax	16.1M	51.2M	96.1M	120.1M	193.5M	203.2M
Total Other Income Expense Net	30.9M	9.9M	(4.0M)	(28.5M)	(14.5M)	(13.8M)
Net Income	8.4M	36.7M	73.7M	104.5M	146.0M	153.3M
Income Tax Expense	7.7M	13.5M	34.0M	37.3M	57.8M	30.1M
Selling And Marketing Expenses	11.9M	6.8M	6.2M	6.6M	11.1M	9.0M
Net Income From Continuing Ops	8.4M	37.7M	62.1M	82.8M	135.8M	142.5M
Net Income Applicable To Common Shares	8.4M	36.7M	73.7M	104.5M	120.2M	126.2M
Minority Interest	22.2M	23.5M	11.5M	21.7M	10.3M	15.3M
Tax Provision	7.7M	13.5M	34.0M	37.3M	57.8M	60.7M
Net Interest Income	(7.7M)	(7.5M)	(12.0M)	(49.2M)	(59.3M)	(56.3M)
Interest Income	31.5M	7.5M	12.0M	49.2M	56.6M	59.4M
Reconciled Depreciation	20.0M	19.9M	24.7M	35.5M	33.5M	27.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Other Information on Investing in Kilitch Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kilitch Historical Income Statement

About Kilitch Income Statement Analysis

Kilitch Drugs Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Kilitch Drugs income statement Correlations

Kilitch Drugs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kilitch Drugs income statement Accounts

Also Currently Popular

Other Information on Investing in Kilitch Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Other Operating Expenses	+ 0.99	Total Revenue

Net Interest Income	- 0.96	Interest Expense
Interest Income	- 0.94	Net Interest Income
Reconciled Depreciation	- 0.92	Net Interest Income
Net Interest Income	- 0.84	Tax Provision
Net Interest Income	- 0.82	Cost Of Revenue
Net Interest Income	- 0.76	Net Income From Continuing Ops